Preparing for new wave of treatments, Fujifilm drops $55 million for gene therapy center
The preparations to serve biopharma’s explosion of gene therapy pipeline candidates continues.
Seven months ago Thermo Fisher put down $1.7 billion for a rising gene therapy contract manufacturer. Catalent quickly followed up with a $1.2 billion deal for gene therapy play of its own, acquiring the Maryland-based Paragon Bioservices. And now, Fujifilm is expanding its own capabilities in the field — with the Japanese conglomerate investing $120 million into the field and building a “Gene Therapy Innovation Center” beside its recently completed base in College Station, Texas.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
